Pediatric Cardiology

, Volume 37, Issue 1, pp 14–23 | Cite as

A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates

  • Liam Mahoney
  • Geetika Shah
  • David Crook
  • Hector Rojas-Anaya
  • Heike Rabe
Review Article

Abstract

Since its discovery in 1975 dobutamine has been used off-label for treating hemodynamic insufficiency in newborns and children. We present a structured literature review of pharmacokinetic and pharmacodynamic data for dobutamine in the pediatric population. Structured searches were conducted to identify relevant articles according to pre-defined inclusion criteria. Where possible, results for the pharmacodynamic and pharmacokinetic effect of dobutamine were reported as pooled data. Forty-six papers met the inclusion criteria. With regard to pharmacodynamic data a number of studies reported significant increases in a number of clinical parameters such as heart rate, blood pressure, cardiac output across a wide range of pediatric populations. With regard to pharmacokinetic data studies reported that the infusion rate was positively correlated to plasma dobutamine concentration. There was great variability with regard to dobutamine clearance between individuals and as to whether it followed first- or zero-order elimination kinetics. While the pharmacodynamic effects of dobutamine appear to reflect the pharmacological profile of the drug, the pharmacokinetic data are difficult to interpret due to inhomogeneity between study populations ages, comorbidities, dobutamine dosages and methodologies. High-quality prospective pharmacokinetic and pharmacodynamic data especially in newborns are urgently required prior to a large randomized study.

Keywords

Dobutamine Neonate Hypotension Pediatric Pharmacodynamic Pharmacokinetic 

Notes

Acknowledgments

A special thanks to Tom Roper and Sarah Butler, Clinical librarians at The Brighton and Sussex University Hospitals NHS Trust, for their help with searching strategies for this review. This literature review will be presented to the European Medicines Agency as part of a Pediatric Investigations Plan for the Neo-Circulation Project. The members of the consortium are outlined below: Chief Investigator: Adelina Pellicer, Madrid, Spain. Principal Project Coordinator: Heike Rabe, Brighton, UK. Local Investigators: Philip Amess, Neil Aiton, David Crook, Ramon Fernandez, Liam Mahoney, Heike Rabe, Hector Rojas-Anaya, Brighton, UK; Vincent Jullien, Thomas Le Saux, Gerard Pons, Paris, France; Frank Biertz, Wolfgang Büter, Armin Koch, Hannover, Germany; Victoria Mielgo, Adolf Valls-i-Soler (in memoriam), Bizkaia, Spain; Wolfgang Göpel, Christoph Härtel, Lübeck, Germany; Haris Kotidis, Mark Turner, Michael Weindling, Liverpool, UK; Claudia Roll, Datteln, Germany; Maria Carmen Bravo, Fernando Cabanas, Madrid, Spain; Simon Bryson, Chesire, UK; Alexandrina Tatu, Adrian Toma, Bucharest, Romania; Gabriela Zaharie, Cluj-Napoca, Romania; Géza Bokodi, Miklós Szabó, Budapest, Hungary; Tibor Ertl, Simone Funke, Pécs, Hungary; Ebru Ergenekon, Kivilcim Gücüyener, Şebnem Soysal, Ankara, Turkey; Christiane Dammann, Olaf Dammann, Jennifer Lee, Boston, US; Neo-Circulation Expert Advisory Board: Tonse N. K. Raju, Bethesda, USA; Nicholas Evans, Sydney, Australia; Stephanie Läer, Düsseldorf, Germany; Silke Mader, Karlsfeld, Germany; Monika Seibert-Grafe, Mainz, Germany. Neo-Circulation Ethics Advisory and Data Monitoring Board: Gorm Greisen, Copenhagen, Denmark; Lena Hellström-Westas, Uppsala, Sweden; Josef Högel, Ulm, Germany.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

246_2015_1263_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
    Alderliesten T, Lemmers PMA, van Haastert IC et al (2014) Hypotension in preterm neonates: low blood pressure alone does not affect neurodevelopmental outcome. J Pediatr 164:986–991. doi:10.1016/j.jpeds.2013.12.042 CrossRefPubMedGoogle Scholar
  2. 2.
    Aslan YY, Koca LL, Mutlu MM et al (2011) Apopitotic effects of dopamine and dobutamine on neutrophils of premature neonates. J Matern Fetal Neonatal Med 24:1155–1158. doi:10.3109/14767058.2010.545914 CrossRefPubMedGoogle Scholar
  3. 3.
    Ballabh P (2010) Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res 67:1–8CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Banner W, Vernon DD, Minton SD, Dean JM (1991) Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med 19:871–873CrossRefPubMedGoogle Scholar
  5. 5.
    Berg RAR, Padbury JFJ (1997) Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. Crit Care Med 25:1247–1251CrossRefPubMedGoogle Scholar
  6. 6.
    Berg RA, Donnerstein RL, Padbury JF (1993) Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions. Crit Care Med 21:678–686CrossRefPubMedGoogle Scholar
  7. 7.
    Berg RA, Padbury JF, Donnerstein RL et al (1993) Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents. J Pharmacol Exp Ther 265:1232–1238PubMedGoogle Scholar
  8. 8.
    Berner M, Oberhänsli I, Rouge JC et al (1989) Chronotropic and inotropic supports are both required to increase cardiac output early after corrective operations for tetralogy of Fallot. J Thorac Cardiovasc Surg 97:297–302PubMedGoogle Scholar
  9. 9.
    Bohn DJ, Poirier CS, Edmonds JF, Barker GA (1980) Hemodynamic effects of dobutamine after cardiopulmonary bypass in children. Crit Care Med 8:367–371CrossRefPubMedGoogle Scholar
  10. 10.
    Clark RH, Bloom BT, Spitzer AR, Gerstmann DR (2006) Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 117:1979–1987. doi:10.1542/peds.2005-1707 CrossRefPubMedGoogle Scholar
  11. 11.
    Conroy S, Choonara I, Impicciatore P et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ 320:79–82CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Coté CJ, Kauffman RE, Troendle GJ, Lambert GH (1996) Is the “therapeutic orphan” about to be adopted? Pediatrics 98:118–123PubMedGoogle Scholar
  13. 13.
    Dalben M, Varkulja G, Basso M et al (2008) Investigation of an outbreak of Enterobacter cloacae in a neonatal unit and review of the literature. J Hosp Infect 70:7–14. doi:10.1016/j.jhin.2008.05.003 CrossRefPubMedGoogle Scholar
  14. 14.
    de Waal K, Kluckow M (2015) Functional echocardiography; from physiology to treatment. Early Hum Dev 86:149–154. doi:10.1016/j.earlhumdev.2010.01.030 CrossRefGoogle Scholar
  15. 15.
    Devictor D, Verlhac S, Pariente D, Huault G (1988) Hemodynamic effects of dobutamine in asphyxiated newborn infants. Arch Fr Pediatr 45:467–470PubMedGoogle Scholar
  16. 16.
    Driscoll DJ (1987) Use of inotropic and chronotropic agents in neonates. Clin Perinatol 14:931–949PubMedGoogle Scholar
  17. 17.
    Driscoll DJ, Gillette PC, Duff DF et al (1979) Hemodynamic effects of dobutamine in children. Am J Cardiol 43:581–585CrossRefPubMedGoogle Scholar
  18. 18.
    EMA (2010) Revised priority list for studies into off-patent paediatric medical products. European Medicines Agency, London, EMA/480197/2010, pp 1–8Google Scholar
  19. 19.
    Filippi L, Pezzati M, Poggi C et al (2007) Dopamine versus dobutamine in very low birthweight infants: endocrine effects. Arch Dis Child Fetal Neonatal Ed 92:F367–F371. doi:10.1136/adc.2006.098566 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gauthier M, van Doesburg N, Lacroix J, Rousseau E (1984) The pharmacology of cardiorespiratory resuscitation in children. Union Med Can 113:106–111PubMedGoogle Scholar
  21. 21.
    Greenough A, Emery EF (1993) Randomized trial comparing dopamine and dobutamine in preterm infants. Eur J Pediatr 152:925–927CrossRefPubMedGoogle Scholar
  22. 22.
    Gupta S, Donn SM (2014) Neonatal hypotension: dopamine or dobutamine? Semin Fetal Neonatal Med 19:54–59. doi:10.1016/j.siny.2013.09.006 CrossRefPubMedGoogle Scholar
  23. 23.
    Gupte S (2002) Perspectives in neonatal shock. Perinatology 4:264–275Google Scholar
  24. 24.
    Habib DM, Padbury JF, Anas NG et al (1992) Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med 20:601–608CrossRefPubMedGoogle Scholar
  25. 25.
    Hamamichi Y, Ichida F, Tsubata S et al (2002) Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease. Circ J 66:63–69CrossRefPubMedGoogle Scholar
  26. 26.
    Harada K, Tamura M, Ito T et al (1996) Effects of low-dose dobutamine on left ventricular diastolic filling in children. Pediatr Cardiol 17:220–225CrossRefPubMedGoogle Scholar
  27. 27.
    Harada K, Tamura M, Toyono M, Yasuoka K (2002) Effect of dobutamine on a Doppler echocardiographic index of combined systolic and diastolic performance. Pediatr Cardiol 23:613–617. doi:10.1007/s00246-002-0017-7 CrossRefPubMedGoogle Scholar
  28. 28.
    Hayabuchi YY, Matsuoka SS, Kuroda YY (1999) Plasma concentrations of atrial and brain natriuretic peptides and cyclic guanosine monophosphate in response to dobutamine infusion in patients with surgically repaired tetralogy of fallot. Pediatr Cardiol 20:343–350CrossRefPubMedGoogle Scholar
  29. 29.
    Hentschel R, Hensel D, Brune T et al (1995) Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants. Biol Neonate 68:318–324CrossRefPubMedGoogle Scholar
  30. 30.
    Hunt RW, Evans N, Rieger I, Kluckow M (2004) Low superior vena cava flow and neurodevelopment at 3 years in very preterm infants. J Pediatr 145:588–592. doi:10.1016/j.jpeds.2004.06.056 CrossRefPubMedGoogle Scholar
  31. 31.
    Hurwitz RA, Siddiqui A, Caldwell RL et al (1990) Assessment of ventricular function in infants and children. Response to dobutamine infusion. Clin Nucl Med 15:556–559CrossRefPubMedGoogle Scholar
  32. 32.
    Jose AB, Niguidula DF, Botros S et al (1981) Hemodynamic effects of dobutamine in children. Anaesthesiology 55:25Google Scholar
  33. 33.
    Kates RE, Leier CV (1978) Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 24:537–541CrossRefPubMedGoogle Scholar
  34. 34.
    Klarr JM, Faix RG, Pryce CJ, Bhatt-Mehta V (1994) Randomized, blind trial of dopamine versus dobutamine for treatment of hypotension in preterm infants with respiratory distress syndrome. J Pediatr 125:117–122. doi:10.1016/S0022-3476(94)70137-7 CrossRefPubMedGoogle Scholar
  35. 35.
    Kleiber N, Tromp K, Mooij MG et al (2014) Ethics of drug research in the pediatric intensive care unit. Paediatr Drugs. doi:10.1007/s40272-014-0101-5 Google Scholar
  36. 36.
    Kluckow M (2005) Low systemic blood flow and pathophysiology of the preterm transitional circulation. Early Hum Dev 81:429–437. doi:10.1016/j.earlhumdev.2005.03.006 CrossRefPubMedGoogle Scholar
  37. 37.
    Kwapisz MM, Neuhäuser C, Scholz S et al (2009) Hemodynamic effects of dobutamine and dopexamine after cardiopulmonary bypass in pediatric cardiac surgery. Paediatr Anaesth 19:862–871. doi:10.1111/j.1460-9592.2009.03101.x CrossRefPubMedGoogle Scholar
  38. 38.
    Lorenz JM, Kleinman LI, Ahmed G, Markarian K (1995) Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics 96:484–489PubMedGoogle Scholar
  39. 39.
    Martinez AM, Padbury JF, Thio S (1992) Dobutamine pharmacokinetics and cardiovascular responses in critically ill neonates. Pediatrics 89:47–51PubMedGoogle Scholar
  40. 40.
    Michelfelder EC, Witt SA, Khoury P, Kimball TR (2003) Moderate-dose dobutamine maximizes left ventricular contractile response during dobutamine stress echocardiography in children. J Am Soc Echocardiogr 16:140–146. doi:10.1067/mje.2003.3 CrossRefPubMedGoogle Scholar
  41. 41.
    Mielgo V, Soler AVI, Rey-Santano C (2014) Dobutamine in paediatric population: a systematic review in juvenile animal models. PLoS ONE 9:e95644CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Milsap RL, Jusko WJ (1994) Pharmacokinetics in the infant. Environ Health Perspect 102(Suppl 11):107–110CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Nakazawa M, Takahashi Y, Aiba S et al (1987) Acute hemodynamic effects of dopamine, dobutamine, and isoproterenol in congested infants or young children with large ventricular septal defect. Jpn Circ J 51:1010–1015CrossRefPubMedGoogle Scholar
  44. 44.
    NEOCIRC Consortium (2012) Dobutamine for NEOnatal CIRCulatory failure defined by novel biomarkers. www.neocirculation.eu. In: http://neocirculation.eu. Accessed 28 Feb 2014
  45. 45.
    Osborn D, Evans N, Kluckow M (2002) Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr 140:183–191. doi:10.1067/mpd.2002.120834 CrossRefPubMedGoogle Scholar
  46. 46.
    Osborn DAD, Evans NN, Kluckow MM (2007) Left ventricular contractility in extremely premature infants in the first day and response to inotropes. Pediatr Res 61:335–340. doi:10.1203/pdr.0b013e318030d1e1 CrossRefPubMedGoogle Scholar
  47. 47.
    Osborn DA, Evans N, Kluckow M et al (2007) Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. Pediatrics 120:372–380. doi:10.1542/peds.2006-3398 CrossRefPubMedGoogle Scholar
  48. 48.
    Osborn DA, Paradisis M, Evans N (2007) The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow. Cochrane Database Syst Rev. doi:10.1002/14651858.CD005090.pub2 Google Scholar
  49. 49.
    Pellicer A (2007) Hipotensión y soporte cardiovascular en el recién nacido de bajo peso. Anales de Pediatría Continuada 5:361–365. doi:10.1016/S1696-2818(07)74160-4 CrossRefGoogle Scholar
  50. 50.
    Perkin RM, Levin DL, Webb R et al (1982) Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr 100:977–983CrossRefPubMedGoogle Scholar
  51. 51.
    Platz H, Fries R, Hudec M et al (1983) The prognostic relevance of various factors at the time of the first admission of the patient: retrospective DÖSAK study on carcinoma of the oral cavity. J Maxillofac Surg 11:3–12. doi:10.1016/S0301-0503(83)80005-8 CrossRefPubMedGoogle Scholar
  52. 52.
    Pushparajah K, Wong J, Bellsham-Revell HR et al (2013) MRI catheter stress haemodynamics in hypoplastic left heart syndrome after Fontan completion. Cardiol Young 23:S1–S144CrossRefGoogle Scholar
  53. 53.
    Razavi RS, Baker A, Qureshi SA et al (2001) Hemodynamic response to continuous infusion of dobutamine in Alagille’s syndrome. Transplantation 72:823–828CrossRefPubMedGoogle Scholar
  54. 54.
    Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (2006) Official Journal of the European Union. L 378/1Google Scholar
  55. 55.
    Robel-Tillig E, Knüpfer M, Pulzer F, Vogtmann C (2007) Cardiovascular impact of dobutamine in neonates with myocardial dysfunction. Early Hum Dev 83:307–312. doi:10.1016/j.earlhumdev.2006.06.005 CrossRefPubMedGoogle Scholar
  56. 56.
    Rozé JC, Tohier C, Maingueneau C et al (1993) Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child 69:59–63. doi:10.1136/adc.69.1_Spec_No.59 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Ruelas-Orozco G, Vargas-Origel A (2000) Assessment of therapy for arterial hypotension in critically ill preterm infants. Am J Perinatol 17:95–99CrossRefPubMedGoogle Scholar
  58. 58.
    Ruggieri L, Giannuzzi V, Baiardi P et al (2014) Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. doi:10.1007/s00431-014-2398-z PubMedCentralGoogle Scholar
  59. 59.
    Sakata Y, Iijima T, Yoshida I et al (1991) Effects of dopamine and dobutamine on systemic hemodynamics and myocardial metabolism in children after open heart surgery. Kyobu Geka 44:461–466PubMedGoogle Scholar
  60. 60.
    Sakata Y, Anzai T, Iijima T et al (1992) Effects of dobutamine and isoproterenol on systemic hemodynamics and myocardial metabolism in children after open heart surgery. Kokyu To Junkan 40:65–70PubMedGoogle Scholar
  61. 61.
    Schranz D, Stopfkuchen H, Jüngst BK et al (1982) Hemodynamic effects of dobutamine in children with cardiovascular failure. Eur J Pediatr 139:4–7CrossRefPubMedGoogle Scholar
  62. 62.
    Schwartz PH, Eldadah MK, Newth CJ (1991) The pharmacokinetics of dobutamine in pediatric intensive care unit patients. Drug Metab Dispos 19:614–619PubMedGoogle Scholar
  63. 63.
    Seri I (2001) Neonatal shock: etiology, pathophysiology and management. Prenat Neonatal Med 6:15–26. doi:10.1080/13598630108500263 Google Scholar
  64. 64.
    Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors. Clin Pharmacokinet 27:345–367. doi:10.2165/00003088-199427050-00003 CrossRefPubMedGoogle Scholar
  65. 65.
    Stopfkuchen H, Schranz D, Huth R, Jüngst BK (1987) Effects of dobutamine on left ventricular performance in newborns as determined by systolic time intervals. Eur J Pediatr 146:135–139CrossRefPubMedGoogle Scholar
  66. 66.
    Stopfkuchen H, Queisser-Luft A, Vogel K (1990) Cardiovascular responses to dobutamine determined by systolic time intervals in preterm infants. Crit Care Med 18:722–724CrossRefPubMedGoogle Scholar
  67. 67.
    Stowe CD, Storgion SA, Lee KR, Phelps SJ (1996) Hemodynamic response to intentionally altered flow continuity of dobutamine and dopamine by an infusion pump in infants. Pharmacotherapy 16:1018–1023. doi:10.1002/j.1875-9114.1996.tb03027.x PubMedGoogle Scholar
  68. 68.
    Subhedar NV, Shaw NJ (2003) Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database Syst Rev 3:CD001242Google Scholar
  69. 69.
    Trifonova NA, Ismail-Zade IA, Michelson VA (1994) Value of dobutamine in children surgically treated for portal hypertension. Apropos of 23 cases. Cah Anesthesiol 42:577–581PubMedGoogle Scholar
  70. 70.
    van den Broek MPH, Groenendaal F, Egberts ACG, Rademaker CMA (2010) Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 49:277–294. doi:10.2165/11319360-000000000-00000 CrossRefPubMedGoogle Scholar
  71. 71.
    Yan M, Webster LT, Blumer JL (2002) 3-O-methyldobutamine, a major metabolite of dobutamine in humans. Drug Metab Dispos 30:519–524. doi:10.1124/dmd.30.5.519 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Liam Mahoney
    • 1
  • Geetika Shah
    • 1
  • David Crook
    • 2
  • Hector Rojas-Anaya
    • 1
  • Heike Rabe
    • 1
  1. 1.Academic Department of PaediatricsBrighton and Sussex Medical School, Royal Alexandra Children’s HospitalBrightonUK
  2. 2.Clinical Investigation and Research UnitRoyal Sussex County Hospital, Brighton and Sussex University Hospitals NHS TrustBrightonUK

Personalised recommendations